---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-269400"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:51:55.199428+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics completes enrollment of 135 patients in Phase 2 AMPLIFY-7P study for ELI-002

## Summary
- Phase 2 study ELI-002 7P enrolled 135 mKRAS-driven PDAC patients post-surgery, randomized 2:1 vs observation.
- Interim analysis of disease-free survival (DFS) expected in H1 2025, with possible final analysis in H2 2025.
- Enrollment pace exceeded expectations; patients eligible cross-over to ELI-002 upon progression.
- Primary endpoint is DFS; key secondary endpoints include overall survival and vaccine immunogenicity.
- Previous Phase 1a data showed favorable safety and T-cell responses; SITC 2024 data presented.

## SEC filing metadata
- accession: 0001193125-24-269400
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/0001193125-24-269400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/d858884d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-269400
- JSON: https://secwatch.observer/filing/0001193125-24-269400.json
- Plain text: https://secwatch.observer/filing/0001193125-24-269400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.